Ironwood Pharmaceuticals initiated an internal organizational restructuring that includes cutting up to 100 full-time employees from payroll following a review of unblinded data from the company’s Phase III trials for IW-3718-302, which show that the drug failed to reduce the severity of heartburn in patients with refractory gastroesophageal reflux disease (GERD).
Ad-ventures in Marketing XI
Artificial Intelligence, Business, Data Security, December 2018, Digiceuticals, Doctors, Gastroesophageal Reflux Disease (GERD), Healthcare Communications Agencies, Healthcare Physicians, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome, Issue Archives, Joint Ventures, Marketing & Advertising, Partnerships, Patient Identification, Patients, Pharma, Pharmaceutical Marketing Ventures to Watch, Pharmacy Benefits, Rare Diseases, Rare Disorders, Sales Aids, Siri, Special Features, Start-Ups, TherapistsFor the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.